Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to demonstrate a survival advantage with avelumab for metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared with 14.3 months with best supportive care (Abstract LBA1).
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.
Professor Lourdes Gil Deza, of the Instituto Oncológico Henry Moore, Buenos Aires, discusses her findings on the shortcomings of medical training when it comes to treating transgender patients, and the need to deepen clinical and communication skills to assist this population (Abstract 11002).
Cynthia X. Ma, MD, PhD, of Washington University, discusses results from the ALTERNATE trial, which showed neither fulvestrant nor fulvestrant plus anastrozole significantly improved endocrine-sensitive disease rate compared with anastrozole alone in postmenopausal patients with locally advanced estrogen receptor–positive, HER2-negative breast cancer (Abstract 504).
